Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Karen E. Sheppard"'
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-5 (2022)
Abstract CDK4/6 inhibitors (CDK4/6i) were developed as a cancer therapeutic on the basis of their tumor-intrinsic cytostatic potential, but have since demonstrated profound activity as immunomodulatory agents. While currently approved to treat hormon
Externí odkaz:
https://doaj.org/article/d3b830639fb54c8e817359ba791b5397
Autor:
Lorey K. Smith, Tiffany Parmenter, Margarete Kleinschmidt, Eric P. Kusnadi, Jian Kang, Claire A. Martin, Peter Lau, Riyaben Patel, Julie Lorent, David Papadopoli, Anna Trigos, Teresa Ward, Aparna D. Rao, Emily J. Lelliott, Karen E. Sheppard, David Goode, Rodney J. Hicks, Tony Tiganis, Kaylene J. Simpson, Ola Larsson, Benjamin Blythe, Carleen Cullinane, Vihandha O. Wickramasinghe, Richard B. Pearson, Grant A. McArthur
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-21 (2022)
Different adaptive mechanisms have been reported to reduce the efficacy of mutant BRAF inhibition in melanoma. Here, the authors show BRAF inhibition induces the translational regulation of metabolic genes leading to acquired therapy resistance.
Externí odkaz:
https://doaj.org/article/059612c027f74f17b5f4fdc038786683
Autor:
Riyaben P Patel, Pretashini M Somasundram, Lorey K. Smith, Karen E. Sheppard, Grant A. McArthur
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 3, Pp n/a-n/a (2023)
Abstract Background Cutaneous melanoma is a lethal form of skin cancer with morbidity and mortality rates highest amongst European, North American and Australasian populations. The developments of targeted therapies (TTs) directed at the oncogene BRA
Externí odkaz:
https://doaj.org/article/42e4ac8011584beba3a1c37d0686c779
Autor:
Lok Hang Chan, Peihan Wang, Shatha Abuhammad, Lydia Rui Jia Lim, Joseph Cursons, Karen E. Sheppard, David L. Goode
Publikováno v:
PLoS ONE, Vol 18, Iss 11 (2023)
Externí odkaz:
https://doaj.org/article/45fdcea7d05941a88c6ee4ed0e1f1cf8
Autor:
Elaine Sanij, Katherine M. Hannan, Jiachen Xuan, Shunfei Yan, Jessica E. Ahern, Anna S. Trigos, Natalie Brajanovski, Jinbae Son, Keefe T. Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J. Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J. Deans, Kum Kum Khanna, Linda Mileshkin, Grant A. McArthur, John Soong, Els M. J. J. Berns, Ross D. Hannan, Clare L. Scott, Karen E. Sheppard, Richard B. Pearson
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
Acquired resistance limits the efficacy of PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Here, the authors show that inhibition of RNA polymerase I transcription using CX-5461 increases the therapeutic efficacy of PARPi and ove
Externí odkaz:
https://doaj.org/article/e147f3013f3440d1be5ac0b31368773d
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
The recent advent of targeted and immune-based therapies has revolutionized the treatment of melanoma and transformed outcomes for patients with metastatic disease. The majority of patients develop resistance to the current standard-of-care targeted
Externí odkaz:
https://doaj.org/article/19e9de3ad9304ba795508d994632a10b
Autor:
Jinbae Son, Katherine M. Hannan, Gretchen Poortinga, Nadine Hein, Donald P. Cameron, Austen R. D. Ganley, Karen E. Sheppard, Richard B. Pearson, Ross D. Hannan, Elaine Sanij
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 8 (2020)
Hyperactivation of RNA polymerase I (Pol I) transcription of ribosomal RNA (rRNA) genes (rDNA) is a key determinant of growth and proliferation and a consistent feature of cancer cells. We have demonstrated that inhibition of rDNA transcription by th
Externí odkaz:
https://doaj.org/article/d1352252bad3409b96196916aa6676cf
Autor:
Karen E. Sheppard, Shatha AbuHammad
Publikováno v:
Molecular & Cellular Oncology, Vol 6, Iss 6 (2019)
Cyclin-dependent kinase −4 and −6 (CDK4/6) inhibitors are currently being assessed in clinical trials for the treatment of many cancers including melanoma. While investigating the mechanisms of CDK4/6 inhibitor resistance in melanoma, we uncovere
Externí odkaz:
https://doaj.org/article/8cfcc15c6a47416aa66081cd570b960d
Autor:
Sathyen A. Prabhu, Omar Moussa, Christophe Gonçalves, Judith H. LaPierre, Hsiang Chou, Fan Huang, Vincent R. Richard, Pault Y. M. Ferruzo, Elizabeth M. Guettler, Isabel Soria-Bretones, Laura Kirby, Natascha Gagnon, Jie Su, Jennifer Silvester, Sai Sakktee Krisna, April A. N. Rose, Karen E. Sheppard, David W. Cescon, Frédérick A. Mallette, Rene P. Zahedi, Christoph H. Borchers, Sonia V. del Rincon, Wilson H. Miller
Publikováno v:
Molecular Cancer Therapeutics. 22:192-204
Aberrant cell-cycle progression is characteristic of melanoma, and CDK4/6 inhibitors, such as palbociclib, are currently being tested for efficacy in this disease. Despite the promising nature of CDK4/6 inhibitors, their use as single agents in melan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8fc658755ecfbbd8c0d925809d970fd
https://doi.org/10.1158/1535-7163.mct-22-0092
https://doi.org/10.1158/1535-7163.mct-22-0092
Autor:
Karen E. Sheppard, Jane Oliaro, Grant A. McArthur, Nicole M. Haynes, Anthony T. Papenfuss, Carleen Cullinane, Alison Slater, Riyaben P. Patel, Claire Martin, Laura Kirby, Luciano G. Martelotto, Amanda J. Oliver, Peter K.H. Lau, Lydia Lim, Magnus Zethoven, Kelly M. Ramsbottom, Stefano Mangiola, Emily J. Lelliott
Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring a BRAFV600 mutation. While this triple therapy has potent tumor-intrinsic effects, the impact of this combination on an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4345cc594088fa46130e17ff63a50c05
https://doi.org/10.1158/2326-6066.c.6550431.v1
https://doi.org/10.1158/2326-6066.c.6550431.v1
